Literature DB >> 1656751

Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment.

W G Stetler-Stevenson1, J A Talano, M E Gallagher, H C Krutzsch, L A Liotta.   

Abstract

The proenzyme fragment of the 72 kDa type IV collagenase contains a conserved amino acid sequence, MRKPRCGN(V)PDV, that is shared with other members of the matrix metalloproteinase family, such as interstitial collagenase and stromelysin. This sequence is lost upon the autocatalytic removal of the 80-84 amino acids from the amino terminus of these proenzymes following enzyme activation. The loss of this profragment converts the latent proenzyme species into a stable active enzyme species. In the present study, we demonstrate that this conserved prosegment sequence is an inhibitor of these enzymes and plays a critical role in maintenance of the latent state of the matrix metalloproteinases. Peptides containing the conserved sequence, MRKPRCGNPDV, were capable of inhibiting activated enzyme. Free cysteine was also an effective inhibitor, whereas reduced glutathione was a less effective inhibitor. Oxidized glutathione was not inhibitory. The 72 kDa type IV collagenase holoproenzyme preparations did not contain a free cysteinyl side chain that reacted with the sulfhydryl substitution reagent 5,5'-dithiobis(2-nitrobenzoic acid) (Ellman's reagent). However, addition of ethylenediaminetetraacetic acid to the reaction mixture to generate the apoenzyme form resulted in the detection of titrable sulfhydryl side chains. Based on these data, we postulate that in the latent enzyme state the conserved profragment sequence interacts with the metal atom at the active site through a sulfhydryl-metal atom coordination that is further stabilized by the amino acyl residues surrounding the essential 73Cys residue. Disturbance of this interaction results in enzyme activation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656751     DOI: 10.1097/00000441-199109000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

2.  Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries.

Authors:  G Ferry; J A Boutin; G Atassi; J L Fauchère; G C Tucker
Journal:  Mol Divers       Date:  1997       Impact factor: 2.943

3.  A novel mechanism of latency in matrix metalloproteinases.

Authors:  Mar López-Pelegrín; Miroslaw Ksiazek; Abdulkarim Y Karim; Tibisay Guevara; Joan L Arolas; Jan Potempa; F Xavier Gomis-Rüth
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

4.  Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin.

Authors:  Q A Sang; M K Bodden; L J Windsor
Journal:  J Protein Chem       Date:  1996-04

5.  Peptides based on the conserved predomain sequence of matrix metalloproteinases inhibit human stromelysin and collagenase.

Authors:  A C Hanglow; A Lugo; R Walsky; M Finch-Arietta; L Lusch; M Visnick; N Fotouhi
Journal:  Agents Actions       Date:  1993

6.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression.

Authors:  D Muir
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.